Department of Psychology, Differential Psychology and Personality Research, Philipps-University of Marburg
Marburg, Hesse, 35032, Germany
NCT Number: NCT05208294
Although placebo effects on depressive symptoms are well documented, the underlying mechanisms and moderating factors of expectation effects on mood and depression are poorly understood. Various studies show reduced reward processing in clinical and subclinical depression, presumably due to abnormalities in the dopamine (DA) system. Here, the investigators will test whether expectation-induced mood enhancement is mediated by endogenous DA activity and reward learning, and moderated by individual differences in depression-related personality traits. Healthy participants (N=296) will be tested for potentially relevant personality traits and given an inactive substance (placebo) or a DA D2-receptor antagonist sulpiride (400 mg) in combination with a low vs. high expectation manipulation (fully crossed 2x2 placebo design) before performing a probabilistic reinforcement learning task, an effort expenditure task, and undergo a depressed mood induction procedure. Further, EEG indices will be assessed throughout the tasks.
The investigators expect that positive expectation improves participants' reinforcement learning, increases participants' willingness to make effort in order to obtain reward, and leads to less depressive symptoms as indicated by mood ratings upon depressive mood induction. If the overall effect of positive expectations is mediated by DA, high-dose sulpiride should block expectation-induced effects, i.e., the anticipated enhanced reinforcement learning and effort expenditure as well as mood improvement in the high vs. low expectation group.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Not applicable
Marburg, Hesse, 35032, Germany
The placebo effect, i.e., raising expectations towards a successful treatment by applying an inactive substance, reportedly improves therapeutic outcomes in clinical trials. Although there is supporting evidence for the neurotransmitter dopamine (DA) and reinforcement learning, i.e. learning from reward and punishment, to mediate this effect, to the knowledge of the authors, no study has tested these underpinnings yet. The objective of the present project is to investigate whether expectation-induced mood enhancement is mediated by DA activity and reward learning, and moderated by individual differences in depression-related personality traits. To this end, participants will be told to either receive a placebo (low expectation) or a medicine which is labeled as antidepressant (high expectation) that improves mood. Orthogonal to this expectation manipulation, participants actually receive either 400 mg of sulpiride (sulpiride group) or a placebo (inactive substance group). Sulpiride is a selective D2-recptor antagonist which presumably elevates DA levels in low doses and has been used as an antidepressant. However, as a part of the high expectation group's expectation manipulation, while participants are told to receive an antidepressant, the sulpiride group actually receives a dose that is presumably too high to increase DA levels and produce antidepressant effects. Rather, 400mg of sulpirid presumably leads to a blockade of dopamine receptors and may thereby block expectation placebo effects. Participants then undergo three tasks, in which behavioral and computational markers of reinforcement learning and willingness to make effort in order to obtain reward are investigated. Further, mood ratings upon depressive mood induction will be assessed. In addition to participants behavioral responses, EEG indices will be recorded throughout the tasks. Prior to testing, participants will be asked to fill out questionnaires with regard to personality traits as well as reward response. In order to assess dopamine-related plasma prolactin, the study physician will draw one blood sample (ca. 8 ml) at the beginning of the testing session (at approximately 9 a.m.) and one hour after substance intake (at approximately 10 a.m.), which presumably corresponds with the latency of the peak of the prolactin response to sulpiride. Saliva and gene samples will be collected for hypotheses that are tested in the context of the overarching collaborative research center 289 and preregistered elsewhere.
It is expected that positive expectation improves participants' reinforcement learning, increases participants' willingness to make effort in order to obtain reward, and leads to less depressive symptoms as indicated by mood ratings upon depressive mood induction. If the overall effect of positive expectations is mediated by DA, high-dose sulpiride should block expectation-induced effects, i.e., the anticipated enhanced reinforcement learning and effort expenditure as well as mood improvement in the high vs. low expectation group.
Hypotheses:
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The substituted benzamide sulpiride is a selective D2-receptor antagonist that is generally well tolerated and has a low affinity to histaminergic, cholinergic, serotonergic, adrenergic, or GABA receptors. Sulpiride is slowly absorbed from the gastrointestinal tract and peak serum levels occur at 3 hours . In low doses (50-200 mg), sulpiride presumably blocks presynaptic autoreceptors, thereby elevating DA levels and reducing depressive symptoms, whereas higher doses lead to a predominant blockade of postsynaptic receptors. The dose in the present study (400 mg) is sufficient for behaviorally relevant modulations of dopaminergic processing with minimal risk of side effects. Note that participants in the sulpiride group actually receive a dose that is presumably too high to produce antidepressant effects.
Participants receive an inactive placebo capsule.
Participants will be told by the study clinicians that an antidepressive sulpiride capsule is administrated.
Participants will be told by the study clinicians that an inactive placebo capsule is administrated.
Time frame: Five time points: approximately 3 hours after treatment (i.e., substance intake), approximately 4 hours after treatment, approximately 4.5 hours after treatment, approximately 4.75 hours after treatment, and approximately 5 hours after treatment.
With regard to depressive mood induction: the mean of participants' five mood ratings during and immediately after the mood induction procedure. Participants' current mood will be rated on a 5-point Likert scale ranging from 1 = very slightly or not at all to 5 = extremely.
Time frame: This will be the first task participants undergo approximately 3 hours after treatment (i.e., substance intake) followed by the two other tasks.
With regard to probabilistic reinforcement learning: participants' reward learning rate parameter αG as estimated in computational modeling.
Time frame: This will be the second task participants undergo which follows the probabilistic reinforcement learning task (approximately 4 hours after treatment) followed by the mood induction procedure.
With regard to effort expenditure: The number of participants' choices for the hard task which required more effort.
Time frame: Simultaneously as PANAS (see primary outcome 1).
Several further mood items will be rated on an 8-point scale ranging from 0 = not at all to 8 = very.
Time frame: Approximately 4. 5 hours after treatment (i.e., during the mood induction procedure which follows the probabilistic reinforcement learning task and the EEfRT tasks).
With regard to depressive mood: the late positive potential (LPP) in response to depressive vs. neutral statements, and frontal alpha asymmetry during the 5-minute resting phase immediately after the mood induction procedure.
Time frame: Approximately 3 hours after treatment (i.e., simultaneously during the probabilistic reinforcement learning task).
With regard to probabilistic reinforcement learning: the reward positivity and frontomedial theta power in response to positive vs. negative feedback in the task.
Time frame: For trait aspects: one week to two days prior to the experiment; for state aspects: approximately 30 minutes before treatment.
STADI offers separate scales for anxiety and depression and while enabling differentiation of state and trait aspects, which are rated on a 4-point scale ranging from 1 = not at all to 4 = very.
Time frame: One week to two days prior to the experiment session.
Personality traits with regard to individual differences in reward processing are assessed ranging from 1 = totally disagree to 4 = totally agree.
Time frame: One week to two days prior to the experiment session.
Participants' acute stress level are assessed on a 5-point scale ranging from 0 = never to 4 = very often, with a focus on psychophysiological stress aspects.
Time frame: One week to two days prior to the experiment session.
Participants' somatosensory amplification in the development of side effects/nocebo effects are assessed on a 5-point scale ranging from 1 to 5. A higher total score indicates greater symptom amplification.
Time frame: One week to two days prior to the experiment session.
A short scale for assessing the Big Five dimensions of personality. Statements with regard to personality are rated on a 5-point scale ranging from 1 = disagree strongly to 5 = agree strongly.
Time frame: One week to two days prior to the experiment session.
Self-rating scale with regard to depressiveness which is scored on a scale of 0-3 in a list of four statements arranged in increasing severity about depressive symptoms. Higher scores indicate higher degree of the presence and intensity of mood symptoms.
Time frame: Approximately 30 minutes prior to treatment.
Assessment of side effects of clinical and experimental therapeutic interventions which is based on the statistics of the Food and Drug Administration, USA.
Time frame: Approximately 30 minutes prior to treatment.
Self-report questionnaire about participants' experience, expectation and current state with regard to the treatment (i.e., sulpiride intake) are assessed on a 11-point scale ranging from 0 to 10, while higher scores indicate stronger degree of expectancy.
Time frame: Approximately 30 minutes prior to treatment.
Measure of response to a wide range of rewards with regard to reward-related abnormalities in depression and other disorders. Higher scores indicate stronger responding to rewards.
Time frame: Approximately 30 minutes prior to treatment.
Assessment of hedonic tone and its absence, i.e., anhedonia.
Time frame: For trait level, one week to two days prior to the experiment session; for state level, approximately 30 minutes prior to treatment.
Assessment of positive and negative affect on the trait and state level, respectively.
Time frame: One week to two days prior to the experiment session.
Assessment of individual trait dispositions in both anticipatory and consummatory experiences of pleasure.
Time frame: One week to two days prior to the experiment session.
Assessment of anhedonia as well as negative affectivity.
Time frame: One week to two days prior to the experiment session.
Assessment of dispositional agentic extraversion and negative affectivity.
Time frame: One week to two days prior to the experiment session.
Assessment of dispositional agentic extraversion and negative affectivity.
Philipps University Marburg
Other
Acronym: CRC289A07
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06285916
Behavior, Behavioral Symptoms
Bentonville, Arkansas, United States
View Trial DetailsNCT06139016
Behavior, Behavioral Symptoms
New Haven, Connecticut, United States
View Trial DetailsNCT06942637
Adolescents, Anxiety
Bandung, West Java, Indonesia
View Trial DetailsNCT04276259
Behavior, Behavioral Symptoms
Pittsburgh, Pennsylvania, United States
View Trial Details